Investor Presentation - First Six Months of 2021
66
Investor presentation
First six months of 2021
Novo Nordisk obesity pipeline supports efforts to close the
treatment gap
Innovation curve
Novo Nordisk's current pipeline is closing the treatment gap
%
New body weight set point
0
Established prediction
5
of WL outcome
Normalised weight
10
25-30% WL
15
Oral product
20
20
Semaglutide 2.4 mg
17-18% *WL
Targeting specific patient
segments/needs
25
SaxendaⓇ
30
Maturation of innovation
6-8% WL
Today
Weight loss over time
Today's marketed
treatment options
Semaglutide 2.4 mg
(WegovyTM 1)
Pipeline
Bariatric surgery
*when using a trial product estimand, 1 Approved in the US
Sources: A. Long-term Drug Treatment for Obesity: A Systematic and Clinical Review; Susan Z. Yanovski, MD; Jack A. Yanovski, MD, PHD JAMA. 2014; 311(1):74-86; B. Treatment of Obesity: Weight Loss and Bariatric Surgery; Bruce M.
Wolfe, Elizaveta Kvach and Robert H. Eckel; Circulation Research. 2016; 118:1844-1855; WL: Weight loss
Novo NordiskⓇView entire presentation